Targeting the Cystine/Glutamate Antiporter System xc⁻ in Cancer-Induced Bone Pain

Persistent Link:
http://hdl.handle.net/10150/594941
Title:
Targeting the Cystine/Glutamate Antiporter System xc⁻ in Cancer-Induced Bone Pain
Author:
Slosky, Lauren M.
Issue Date:
2015
Publisher:
The University of Arizona.
Rights:
Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.
Embargo:
Release 01-Aug-2016
Abstract:
Many common cancers, including breast, prostate and lung cancers, have a propensity to metastasize to bone. Although these cancers go undetected in their native tissues, bone metastases often produce excruciating pain, the etiology of which is poorly understood. Cancer-induced bone pain (CIBP) is not well-controlled with existing medications, severely compromising patient quality of life. While CIBP is multifaceted, increased level of the excitatory neurotransmitter glutamate in the bone-tumor microenvironment may contribute to the pain state. Here, we demonstrate for the first time a relationship between reactive oxygen/nitrogen species, glutamate in the bone-tumor microenvironment and pain behaviors. The murine mammary adenocarcinoma cell line 66.1 is found to release glutamate via the cystine/glutamate antiporter system xc⁻. In a syngeneic model of breast CIBP in which 66.1 cells are inoculated into the femur intramedullary space, administration of sulfasalazine, an established system xc⁻ inhibitor and anti-inflammatory agent, reduces femur glutamate level and attenuates CIBP-related behaviors. Peroxynitrite, a reactive nitrogen species known to be generated in breast tumors, is shown to drive 66.1 system xc⁻ functional expression and tumor cell glutamate release. The elimination of peroxynitrite with the redox modulators FeTMPyP or SRI10 not only modulates tumor cell system xc⁻ functional expression in vitro and in vivo, significantly altering glutamate levels, but also assuages CIBP. In sum, we demonstrate that pharmacological inhibition of system xc⁻ transport attenuates CIBP-related behaviors. These data support a role for tumor-derived glutamate in CIBP and validate system xc⁻ an analgesic target in this pain state.
Type:
text; Electronic Dissertation
Keywords:
Cancer pain; Glutamate; Peroxynitrite; Peroxynitrite decomposition catalyst; Superoxide; Medical Pharmacology; Bone pain
Degree Name:
Ph.D.
Degree Level:
doctoral
Degree Program:
Graduate College; Medical Pharmacology
Degree Grantor:
University of Arizona
Advisor:
Vanderah, Todd W.

Full metadata record

DC FieldValue Language
dc.language.isoen_USen
dc.titleTargeting the Cystine/Glutamate Antiporter System xc⁻ in Cancer-Induced Bone Painen_US
dc.creatorSlosky, Lauren M.en
dc.contributor.authorSlosky, Lauren M.en
dc.date.issued2015en
dc.publisherThe University of Arizona.en
dc.rightsCopyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.en
dc.description.releaseRelease 01-Aug-2016en
dc.description.abstractMany common cancers, including breast, prostate and lung cancers, have a propensity to metastasize to bone. Although these cancers go undetected in their native tissues, bone metastases often produce excruciating pain, the etiology of which is poorly understood. Cancer-induced bone pain (CIBP) is not well-controlled with existing medications, severely compromising patient quality of life. While CIBP is multifaceted, increased level of the excitatory neurotransmitter glutamate in the bone-tumor microenvironment may contribute to the pain state. Here, we demonstrate for the first time a relationship between reactive oxygen/nitrogen species, glutamate in the bone-tumor microenvironment and pain behaviors. The murine mammary adenocarcinoma cell line 66.1 is found to release glutamate via the cystine/glutamate antiporter system xc⁻. In a syngeneic model of breast CIBP in which 66.1 cells are inoculated into the femur intramedullary space, administration of sulfasalazine, an established system xc⁻ inhibitor and anti-inflammatory agent, reduces femur glutamate level and attenuates CIBP-related behaviors. Peroxynitrite, a reactive nitrogen species known to be generated in breast tumors, is shown to drive 66.1 system xc⁻ functional expression and tumor cell glutamate release. The elimination of peroxynitrite with the redox modulators FeTMPyP or SRI10 not only modulates tumor cell system xc⁻ functional expression in vitro and in vivo, significantly altering glutamate levels, but also assuages CIBP. In sum, we demonstrate that pharmacological inhibition of system xc⁻ transport attenuates CIBP-related behaviors. These data support a role for tumor-derived glutamate in CIBP and validate system xc⁻ an analgesic target in this pain state.en
dc.typetexten
dc.typeElectronic Dissertationen
dc.subjectCancer painen
dc.subjectGlutamateen
dc.subjectPeroxynitriteen
dc.subjectPeroxynitrite decomposition catalysten
dc.subjectSuperoxideen
dc.subjectMedical Pharmacologyen
dc.subjectBone painen
thesis.degree.namePh.D.en
thesis.degree.leveldoctoralen
thesis.degree.disciplineGraduate Collegeen
thesis.degree.disciplineMedical Pharmacologyen
thesis.degree.grantorUniversity of Arizonaen
dc.contributor.advisorVanderah, Todd W.en
dc.contributor.committeememberVanderah, Todd W.en
dc.contributor.committeememberFrench, Edward D.en
dc.contributor.committeememberLargent-Milnes, Tally M.en
dc.contributor.committeememberMantyh, Patrick W.en
dc.contributor.committeememberTome, Margaret E.en
All Items in UA Campus Repository are protected by copyright, with all rights reserved, unless otherwise indicated.